Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I project has completed the first year of its lifecycle at the end of October 2021. With this brief note key results and achievements of the first year are summarized in the sequel....
Within the ProCancer-I project, a total of nine clinical needs will be addressed utilizing artificial intelligence (AI) models trained on ProstateNET – a unified repository of 1.5 million images of prostate MRI acquired across the consortium. In the current landscape...
ProCAncer-I aspires to create the largest interoperable, high-quality multi-parametric Magnetic Resonance Imaging (mpMRI) dataset worldwide/globally comprising more than 11.000 retrospective and more than 6.000 prospective mpMRI examinations, including clinical data,...
Interview with prof. Daniele Regge (Clinical Coordinator of the ProCancer-I project) Q: In the case of prostate cancer there are several tests that can help clinicians in the decision process, for example, prediction algorithms based on PSA blood test and biopsy. Why...
A brief historical survey of European state-of-play, the open issues and the ProCAncer-I approach Over the last decade, Artificial Intelligence (AI) solutions to support the whole value-chain of medical imaging has experienced a considerable acceleration. This...
By the Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF) Champalimaud Foundation (CF) is a private non-profit Portuguese institution, inaugurated in 2010 with the aim of advancing basic and translational world-leading research in...
Presentation of partner FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE)
By the FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) The FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) is a Spanish non-profit organization that carries out...
By the Massachusetts General Hospital (The General Hospital Corp) (QTIM) Our lab, the Quantitative Translational Imaging in Medicine (QTIM) lab, at the Athinoula A. Martinos Center for Biomedical Imaging of the Massachusetts General Hospital (MGH), focuses on...
Newsletter #2 Contents
Apr 6, 2022
Use Cases mapped along the prostate cancer management continuum in the ProCAncer-I Project
Feb 16, 2022
ProCAncer -I Project is part of the five H2020 projects that share the same vision, principles and challenges. These projects are funded under the same Action Line: AI for Health Imaging (Call: H2020-SC1-FA-DTS-2019-1): CHAIMELEON (chaimeleon.eu), EuCanImage...
Jan 25, 2022
Our second winter Newsletter has been released! Read more here: 2nd Winter Newsleter Do not forget to subscribe for our next editions!
Dec 10, 2021
How could AI improve prostate cancer diagnosis? This video from the research group of prof. Daniele Regge (coordinator of the clinical activities) explains AI application to prostate MRI.
📢'Trustworthy AI in medical image analysis'
@EuSoMII Webinar by Kostas Marias
👉30 MAY 2022 - 7:00 PM CEST
AI tool accurately predicts tumour regrowth in cancer patients https://www.theguardian.com/society/2022/apr/23/cancer-ai-tool-predicts-tumour-regrowth?CMP=share_btn_tw
Our statement "Considerations for artificial intelligence clinical impact in oncologic imaging: an AI4HI position paper" is out! @primage_project @EuCanImage @chaimeleon_eu @ProCAncer_I
May is #National_Cancer_Research_Month! Thanks to the spectacular advances made by researchers, more people are living longer and with a good quality of life.
A big thank you to the people who make it happen!
#H2020 #healthIT #AI #Cancer #EU_HEALTH #NCRM22 #ResearchSavesLives
Hoy hemos realizado la 1a biopsia robótica de próstata dirigida en RM de la nueva @ClinicaGirona. Unico centro en #Espana en realizar este procedimiento preciso, rápido, no invasivo y seguro para detectar el #cáncerdepróstata, habiéndo realizado +100